GrayBug Announces Presentation at the OIS@AAO Drug Delivery Company Showcase


Baltimore, MD – November 12, 2015 – GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, said that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, will present a brief corporate overview at the Drug Delivery Company Showcase at 9:00 am PST today, November 12, during the Ophthalmology Innovation Summit (OIS) in Las Vegas, NV.

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies. It is held just prior to the American Academy of Ophthalmology Annual Meeting, which begins on November 14, 2015 in Las Vegas.

About GrayBug, Inc.

GrayBug was founded in September 2011 as a spin-out of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to a few times per year (as few as twice per year). These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products. GrayBug is initially focused on developing its own products for the treatment of wet AMD and glaucoma.

GrayBug’s technologies were co-developed by GrayBug founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with GrayBug cofounders, and leading ophthalmology clinicianscientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD. The technologies were licensed from Johns Hopkins University. For more information, please visit www.graybug.com.

Related News

Press release

Graybug Vision Expands Executive Leadership Team with Key Hires

Redwood City, CA – December 11, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced Read more…

Press release

Graybug Vision to Participate in Upcoming Industry Conferences

Redwood City, CA – November 6, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced Read more…

Press release

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration

– Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening Read more…